Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 1;20(4):363-372.
doi: 10.4103/jmas.jmas_272_23. Epub 2024 Oct 9.

A systematic review and meta-analysis of efficacy of vasopressin as a vasoconstrictive and uterotonic drug in laparoscopic myomectomy

Amrita Balachandran  1 , R K Mishra  1 , A Ouma Effie  2 , Akshay Raghunathan  3 , Anoopa Mathew  4 , S Archana  5
Affiliations

A systematic review and meta-analysis of efficacy of vasopressin as a vasoconstrictive and uterotonic drug in laparoscopic myomectomy

Amrita Balachandran et al. J Minim Access Surg. .

Abstract

Introduction: Laparoscopic myomectomy is a commonly performed operation with fast recovery and excellent results. However, haemorrhagic nature of the operation mandates us to use variety of vasoconstrictive and uterotonic agents. Amongst which, one of them is vasopressin. It is a synthetic antidiuretic hormone analogue which has been in common use as a vasoconstrictive agent in various surgical procedures including laparoscopic myomectomy.

Methods: A meta-analysis of randomised controlled trials published from 2013 to 2023 (10 years) comparing the use of vasopressin against other drug or placebo or different doses of vasopressin was performed. The outcome measures were intraoperative blood loss, need for blood transfusion, difference in the haemoglobin (Hb) and haematocrit (Hct).

Results: We identified 176 articles through the study search, amongst which 12 articles were included for the meta-analysis. There was a significant heterogeneity in the studies with moderate risk of bias in eight studies and low risk of bias in four studies. Compared to placebo, vasopressin showed significantly lower odds need of blood transfusion (odds ratio [OR] 0.28, 95% confidence interval [CI]: 0.13-0.61, P = 0.002) and significantly lower pre-post fall in Hb (OR -3.12, 95% CI: -4.63--1.60, P < 0.0001). However, there was no statistically significant difference in intraoperative blood loss (OR -0.56 (95% CI: -2.04-0.92, P = 0.46) and pre-post fall in Hct (OR -0.94, 95% CI: -1.96-0.07, P > 0.05). Compared to other drug (epinephrine, misoprostol and octreotide acetate), vasopressin showed no significant superiority in controlling blood loss ( P > 0.05). Even the two doses of vasopressin (dilute vs. concentrated) showed no statistically significant difference between surgical blood loss and need for blood transfusion ( P > 0.05).

Conclusion: Vasopressin is an efficacious drug to be used for controlling blood loss, decreasing blood transfusion requirement and maintaining Hb and Hct during laparoscopic myomectomy.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Preferred Reporting Items for Systematic Reviews and Meta-Analyses flowchart
Figure 2
Figure 2
(a) Forest plot for need of BT (vasopressin vs. placebo). (b) Funnel plot of need of BT (vasopressin vs. placebo), Egger’s test P = 0.05. OR: Odds ratio, CI: Confidence interval, BT: Blood transfusion
Figure 3
Figure 3
(a) Forest plot of intraoperative blood loss (vasopressin vs. placebo). (b) Funnel plot of intraoperative blood loss (vasopressin vs. placebo), Egger’s test P = 0.002. SD: Standard deviation, CI: Confidence interval, SMD: Standardized mean difference, SE(SMD): Standard error of the standardized mean difference
Figure 4
Figure 4
(a) Forest plot of pre-post haemoglobin (Hb) difference (vasopressin vs. placebo). (b) Funnel plot of pre–post Hb difference (vasopressin vs. placebo), egger test P < 0.0001. SD: Standard deviation, CI: Confidence interval, SMD: Standardized mean difference, SE(SMD): Standard error of the standardized mean difference
Figure 5
Figure 5
(a) Forest plot of pre–post haematocrit (Hct) difference (vasopressin vs. placebo). (b) Funnel plot of pre–post Hct difference (vasopressin vs. placebo). SD: Standard deviation, CI: Confidence interval, SMD: Standardized mean difference, SE(SMD): Standard error of the standardized mean difference
Figure 6
Figure 6
(a) Forest plot of intraoperative blood loss (vasopressin vs. other drug). (b) Funnel plot of intraoperative blood loss (vasopressin vs. other drug). SD: Standard deviation, CI: Confidence interval, SMD: Standardized mean difference, SE(SMD): Standard error of the standardized mean difference
Figure 7
Figure 7
(a) Forest plot of need of BT (vasopressin vs. other drug). (b) Funnel plot of need of BT (vasopressin vs. other drug). OR: Odds ratio, CI: Confidence interval
Figure 8
Figure 8
(a) Forest plot of pre-post haemoglobin (Hb) difference (vasopressin vs. other drug). (b) Funnel plot of pre–post Hb difference (vasopressin vs. other drug). SD: Standard deviation, CI: Confidence interval, SMD: Standardized mean difference, SE(SMD): Standard error of the standardized mean difference
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Cheng LC, Li HY, Gong QQ, Huang CY, Zhang C, Yan JZ. Global, regional, and national burden of uterine fibroids in the last 30 years: Estimates from the 1990 to 2019 Global Burden of Disease Study. Front Med (Lausanne) 2022;9:1–15. - PMC - PubMed
    1. Choudhary A, Inamdar SA, Sharma U. Pregnancy with uterine fibroids: Obstetric outcome at a tertiary care hospital of central India. Cureus. 2023;15:e35513. - PMC - PubMed
    1. Alomar O, Abu-Zaid A, Jamjoom MZ, Almubarki AA, Alsehaimi SO, Alabdrabalamir S, et al. Prophylactic vasopressin to reduce intraoperative blood loss and associated morbidities during myomectomy: A systematic review and meta-analysis of 11 controlled trials. J Gynecol Obstet Hum Reprod. 2022;51:102485. - PubMed
    1. Protopapas A, Giannoulis G, Chatzipapas I, Athanasiou S, Grigoriadis T, Kathopoulis N, et al. Vasopressin during laparoscopic myomectomy: Does it really extend its limits? J Minim Invasive Gynecol. 2019;26:441–9. - PubMed
    1. Lee EJ, Park SJ, Kim Y, Lim H, Lee S, Yim GW, et al. Effect and safety of diluted vasopressin injection on bleeding during robot-assisted laparoscopic myomectomy: A protocol for a randomised controlled pilot trial. BMJ Open. 2022;12:e056145. - PMC - PubMed

LinkOut - more resources